647 related articles for article (PubMed ID: 24816306)
1. Prostate cancer: measuring PSA.
Pezaro C; Woo HH; Davis ID
Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
[TBL] [Abstract][Full Text] [Related]
2. The role of prostate-specific antigen in light of new scientific evidence.
Hernández C; Morote J; Miñana B; Cózar JM
Actas Urol Esp; 2013 Jun; 37(6):324-9. PubMed ID: 23608183
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer: prostate-specific antigen testing is not effective.
Hitzeman N; Molina M
Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
[No Abstract] [Full Text] [Related]
5. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
7. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance for prostate cancer: a review.
Klotz L
Arch Esp Urol; 2011 Oct; 64(8):806-14. PubMed ID: 22052761
[TBL] [Abstract][Full Text] [Related]
9. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
10. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
11. Rising prostate specific antigen after radical prostatectomy: a case based review.
Nasr R; Goldenberg SL
Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
[TBL] [Abstract][Full Text] [Related]
12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
14. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
15. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
[TBL] [Abstract][Full Text] [Related]
16. PSA-based screening for prostate cancer. Too many adverse effects.
Prescrire Int; 2012 Sep; 21(130):215-7. PubMed ID: 23016259
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
18. [Proper use of prostate specific antigen].
Barthélémy Y; Chopin D; Abbou CC
Rev Prat; 1994 Mar; 44(5):617-9. PubMed ID: 7520597
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen-based prostate cancer screening: Past and future.
Alberts AR; Schoots IG; Roobol MJ
Int J Urol; 2015 Jun; 22(6):524-32. PubMed ID: 25847604
[TBL] [Abstract][Full Text] [Related]
20. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
